Systemic effects of chronic obstructive pulmonary disease

By Alvar Agusti, A. Noguera, J. Sauleda, E. Sala, J. Pons, X. Busquets. European Respiratory Journal, 2003

1,066 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Persistent Systemic Inflammation is Associated with Poor Clinical Outcomes in COPD: A Novel Phenotype (2012, background): “Several studies have previously reported elevated levels of circulating WBC, CRP, IL-6, IL-8, fibrinogen and TNFa in patients with clinically stable COPD [8,28–37].”
Mortality in COPD: role of comorbidities (2006, background): “Recently, some evidence has implicated systemic and pulmonary inflammation as the common link between COPD and certain comorbid conditions, such as lung cancer, cardiovascular disease and cachexia [ 35 , 36].”
Chronic obstructive pulmonary disease phenotypes: the future of COPD. (2010, background): “If defined by the presence of elevated biomarkers (including C-reactive protein, serum amyloid A, proinflammatory cytokines IL-6 and IL-8, tumor necrosis factor a, and leukocytes), systemic inflammation does not appear to be present in every patient with COPD (41, 42).”
Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis (2004, background): “4 10 Whether systemic inflammation is present in stable COPD and whether it is wholly or partially responsible for these associations is controversial.”
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. (2007, background): “COPD itself also has significant extrapulmonary (systemic) effects that lead to comorbid conditions (5).”